The preclinical and early clinical evidence supports IL-8 and CXCR1/2 inhibition as a rational and promising therapeutic strategy, particularly in tumors characterized by a proinflammatory, neutrophil- and MDSC-enriched microenvironment, such as PC. This evidence concerns the gene CXCL8 and pachyonychia congenita.